Related Experiment Videos
Effect of niacin on atherosclerotic cardiovascular disease
1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Insights
Niacin significantly reduced cardiovascular events and mortality in major trials. This evidence supports niacin
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Pharmacology
Background:
- Niacin (nicotinic acid) has been investigated for its effects on cardiovascular health.
- Multiple clinical trials have assessed its efficacy in preventing cardiovascular events.
Purpose of the Study:
- To evaluate the evidence from clinical trials on niacin's role in preventing or treating atherosclerotic cardiovascular disease.
Main Methods:
- Review of 6 major clinical trials with cardiovascular endpoints.
- Analysis of niacin monotherapy (Coronary Drug Project) and combination therapy outcomes.
Main Results:
- Niacin monotherapy in the Coronary Drug Project significantly decreased recurrent myocardial infarction and cerebrovascular events.
- Long-term follow-up showed a decrease in total mortality with niacin monotherapy.
- Five additional trials using niacin in combination therapy demonstrated significant benefits, except in patients with normal baseline cholesterol.
Conclusions:
- Strong and consistent clinical trial evidence supports the use of niacin for preventing and treating atherosclerotic cardiovascular disease.
Abstract:
Niacin has been studied in 6 major clinical trials with cardiovascular endpoints. The Coronary Drug Project (CDP) was the largest of these trials and the only one to use niacin monotherapy affecting cardiovascular outcomes: recurrent myocardial infarction and cerebrovascular events were significantly decreased. After long-term (15 years) follow-up, total mortality was also found to be decreased. The other 5 trials used varying combinations of niacin with other pharmacologic agents, examining coronary and total mortality, coronary events, and angiographic progression/regression. Significant benefit was found in all trials except for one in patients with normal cholesterol levels at entry. Thus, the use of niacin to prevent or treat atherosclerotic cardiovascular disease is based on strong and consistent evidence from clinical trials.